Cargando…

Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro

Detalles Bibliográficos
Autores principales:	Schwameis, Richard, Sauermann, Robert, Fille, Manfred, Ligios, Maria L Camuz, Zeitlinger, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313248/ http://dx.doi.org/10.1186/1471-2210-8-S1-A56

Ejemplares similares

Does pulmonary surfactant generally affect antimicrobial activity?
por: Schwameis, Richard, et al.
Publicado: (2012)

Antimicrobial activity of antibiotics in urine under different physiological conditions
por: Burian, Angela, et al.
Publicado: (2010)

Cefepime in critically ill patients: continuous infusion versus intermittent regimen
por: Georges, B, et al.
Publicado: (2001)

Heterogeneous penetration of cefpirome and moxifloxacin into abscesses after simultaneous administration in humans
por: Sauermann, Robert, et al.
Publicado: (2010)

Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens
por: Oesterreicher, Zoe, et al.
Publicado: (2017)

Therapy of malignant intracranial hypertension by lumbar cerebrospinal fluid drainage
por: Münch, E, et al.
Publicado: (2000)

EHMTI-0386. Chronic subdural hematoma and spinal cerebrospinal fluid leak and in non-geriatric patients
por: Beck, J, et al.
Publicado: (2014)

Abstracts from hydrocephalus 2018: the tenth meeting of the International Society for Hydrocephalus and Cerebrospinal Fluid Disorders
Publicado: (2018)

Abstracts from Hydrocephalus 2019: The Eleventh Meeting of the International Society for Hydrocephalus and Cerebrospinal Fluid Disorders
Publicado: (2019)

Abstracts from Hydrocephalus 2021: The Thirteenth Meeting of the International Society for Hydrocephalus and Cerebrospinal Fluid Disorders
Publicado: (2021)

Changes in C-type natriuretic peptide (CNP) levels in the plasma and cerebrospinal fluid of the patients with subarachnoid hemorrhage
por: Ikeda, K, et al.
Publicado: (1999)

Characterization of colistin tissue pharmacokinetics by microdialysis
por: Matzneller, Peter, et al.
Publicado: (2012)

1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
por: Liu, Jiajun, et al.
Publicado: (2018)

Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis
por: Mezochow, Alyssa, et al.
Publicado: (2019)

[(11)C]Elacridar as a novel P-glycoprotein PET tracer, assessment of whole-body distribution and radiation dosimetry in humans
por: Bauer, Martin, et al.
Publicado: (2011)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Tissue pharmacokinetics of individual macrolides support observed differences in development of bacterial resistance
por: Krasniqi, Shaip, et al.
Publicado: (2010)

160. Antimicrobial Prescribing Patterns in Bloodstream Infections Caused by Cefepime-Susceptible Extended Spectrum β-lactamase Enterobacterales
por: O’Rourke, Emerald, et al.
Publicado: (2022)

Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[(11)C]verapamil PET
por: Bauer, Martin, et al.
Publicado: (2010)

A PET microdosing study with the P-glycoprotein inhibitor tariquidar
por: Bauer, Martin, et al.
Publicado: (2012)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes
por: Hackel, Meredith, et al.
Publicado: (2018)

2129. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
por: Hackel, Meredith, et al.
Publicado: (2023)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
por: Crandon, Jared L., et al.
Publicado: (2015)

2136. In Vitro Activity of Nacubactam (OP0595) Combined with Cefepime against Carbapenem-resistant Enterobacterales Isolated in Japan
por: Yanagihara, Katsunori, et al.
Publicado: (2023)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)
por: Purdy, Andrew Scott, et al.
Publicado: (2023)

520. Development of Cefepime-taniborbactam MIC Antimicrobial Susceptibility Test (AST) for Enterobacterales and Pseudomonas aeruginosa on MicroScan Dried Gram-negative MIC Panels
por: Fernandez, Enrique J, et al.
Publicado: (2022)

342. Time to Antimicrobial De-escalation/Discontinuation After Implementation of Cerebrospinal Fluid Polymerase Chain Reaction Tool
por: Chicoineau, Michelle, et al.
Publicado: (2018)

Quality Assessment of Process Measures in Antimicrobial Stewardship: Concordance of Cefepime Indication Without Automatic Prospective Approval in Computerized Provider Order Entry
por: Lee, Tiffany, et al.
Publicado: (2017)

2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
por: Gerges, Bahgat Z, et al.
Publicado: (2023)

A combined accelerator mass spectrometry/positron emission tomography microdose study to assess the plasma and brain tissue pharmacokinetics of (11)C- and (14)C-labelled verapamil in healthy volunteers
por: Wagner, Claudia C, et al.
Publicado: (2008)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

2528. Cefepime Induced Neurotoxicity in Patients With or Without a History of Seizures
por: Baalbaki, Nadeem, et al.
Publicado: (2023)

2178. Resistance to Cefepime/Taniborbactam in NDM-1 -Are We Losing the Battle against MDROs?
por: Ono, Daisuke, et al.
Publicado: (2023)

26. in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism
por: Castanheira, Mariana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kldisuiore567fdj49ldti3895